What drove the intraday jump in TLIK.F stock today?

The intraday gain came with a gap from **€0.26** to **€0.38** and modest volume of **600** shares. No major public earnings were posted; short-covering or a liquidity trade likely pushed the price higher on XETRA.

What is Meyka AI's short-term forecast for TLIK.F stock?

Meyka AI's forecast model projects a monthly price of **€0.27**, an implied downside of **-28.95%** versus the current **€0.38**. Forecasts are model-based projections and not guarantees.

Should investors buy TLIK.F stock after the intraday rise?

Given weak liquidity, negative EPS, and low current ratio, Meyka AI assigns a **B (HOLD)** grade. Investors should prioritise risk control and await clearer volume-backed moves or company updates.

What price targets and risks apply to TLIK.F stock?

We outline a conservative target **€0.20** (-47.37%) and an optimistic target **€0.60** (+57.89%). Key risks are low liquidity, negative cash flow, and limited corporate scale.

DE Stocks

TLIK.F up 15% intraday 13 Feb 2026 (Arzneiwerk AG XETRA): key outlook

ByDanny Kontos February 13, 2026February 13, 2026

TLIK.F stock led XETRA gainers on 13 Feb 2026, jumping 15.15% to €0.38 intraday. The move followed a low-volume gap from €0.26 at the open, with 600 shares traded versus a 50-day average volume of 656. Arzneiwerk AG VIDA (TLIK.F) trades on XETRA in Germany and remains highly volatile. We examine why price moved, how fundamentals stack up, and what our models project for short-term traders.